The cellular therapy from Israel’s Kadimastem (see here previously) was able to slow down the progression of ALS in its first human clinical trial on ten patients. Kadimastem’s Vice President of R&D Michal Izrael describes the treatment and the next … Continue reading →

As reported (here) previously, the stem cell ALS therapy developed by Israel’s Kadimastem showed promise in the lab. Now, early results from human trials at Hadassah hospital in Jerusalem show that it has significantly slowed down disease progression without major … Continue reading →

The US FDA has just given Orphan status to the ALS treatment being developed by Israel’s Kadimastem (see here). The designation qualifies the company for various development incentives and less rigorous bureaucracy. Kadimastem expects results of its Israeli clinical trials … Continue reading →

Israel’s Kadimastem’s recent news includes success in pre-clinical tests of its stem cell treatment for ALS. The technology also induces pancreatic cells to produce insulin and Kadimastem has begun research with Ramot, Tel Aviv University’s technology transfer company. http://www.israel21c.org/headlines/stem-cell-therapy-for-als-diabetes/

Whilst at Israel’s Weizmann Institute, molecular geneticist Professor Michel Revel developed treatments for MS, ALS and diabetes. Now at 75 years of age, he works at his biotech Kadimastem developing pluripotent stem cells as a regenerative medicine solution for all … Continue reading →